Business Context and Reporting Period
This Form 8-K is a current report filed by Envoy Medical, Inc. on February 5, 2026. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbols COCH (Class A Common Stock) and COCHW (Redeemable Warrants). The registrant is classified as an emerging growth company.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on corporate governance and executive compensation actions.
Material Changes
The primary material event reported is the approval of stock option awards to senior executives under the Company's 2023 Equity Incentive Plan:
- CEO Brent Lucas: Awarded options to purchase 200,000 shares of Class A Common Stock.
- Interim CFO Robert Potashnick: Awarded options to purchase 15,000 shares of Class A Common Stock.
- Exercise Price: Set at $0.53 per share, equal to the closing price on the Award Date.
- Vesting Schedule: 25% vests after one year; the remainder vests pro rata over the subsequent 36 months.
- Expiration: Options expire 10 years after the Award Date.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of specific risks and contingencies beyond the standard disclosure of the equity award terms.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2023 Equity Incentive Plan to assess remaining capacity for future grants.
- Confirm the dilution impact of the 215,000 newly issued options on existing shareholders.
- Review the Company's most recent Form 10-K for the fiscal year ended December 31, 2024, to understand the broader context of executive compensation and financial health.
- Monitor the stock price relative to the $0.53 exercise price to evaluate the potential value of these awards.